Deroximel DR Capsule (Enteric Coated Pellets)

Introduction

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is a medication used in the treatment of multiple sclerosis (MS). It is an oral fumaric acid ester and belongs to a class of drugs known as fumarates, which have been shown to have neuroprotective and anti-inflammatory effects.

Uses

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is primarily used to manage and treat relapsing forms of multiple sclerosis (MS). It helps reduce the frequency of MS relapses and slows down the progression of disability in affected individuals.

Brand Name	Deroximel DR
Type	Capsule (Enteric Coated Pellets)
Weight	231 mg
Generic	Diroximel Fumarate
Manufacturer	Renata Limited
Available in	English বাংলা

Mechanism of Action

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is thought to work through multiple mechanisms, including:

Activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which promotes antioxidant responses and reduces oxidative stress.
Reduction of inflammation by modulating immune responses.
Potential neuroprotective effects that may contribute to the preservation of neuronal function.

How Long Does It Take to Work?

The therapeutic effects of Deroximel DR Capsule (Enteric Coated Pellets) 231 mg may take several months to become noticeable. Patients often begin to see improvements in the frequency of relapses and progression of disability within 3 to 6 months of starting treatment, although the full benefit may take longer to achieve.

Absorption

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is well absorbed following oral administration. It is converted to its active form, monomethyl fumarate, in the body, which is then absorbed into the bloodstream and distributed throughout the body.

Route of Elimination

The primary route of elimination for Deroximel DR Capsule (Enteric Coated Pellets) 231 mg and its active metabolite is through the urine. The drug and its metabolites are excreted mainly via the kidneys.

Dosage

Blood Tests Prior to Initiation of Diroximel: Obtain the following prior to treatment with Diroximel:

A complete blood cell count (CBC), including lymphocyte count
Serum aminotransferase, alkaline phosphatase, and total bilirubin levels

Dosing Information: The starting dosage for Diroximel is 231 mg twice a day orally. After 7 days, the dosage should be increased to the maintenance dosage of 462 mg (administered as two 231 mg capsules) twice a day orally. Temporary dosage reductions to 231 mg twice a day may be considered for individuals who do not tolerate the maintenance dosage. Within 4 weeks, the recommended dosage of 462 mg twice a day should be resumed. Discontinuation of Diroximel should be considered for patients unable to tolerate return to the maintenance dosage. Administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to Diroximel dosing may reduce the incidence or severity of flushing.

Administration Instructions: Swallow Diroximel capsules whole and intact. Do not crush or chew, or sprinkle the capsule contents on food. If taken with food, avoid a high-fat, high-calorie meal/snack; the meal/snack should contain no more than 700 calories and no more than 30 g fat.

The usual dosage of Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is 462 mg taken orally twice daily. Dosage may be adjusted based on individual patient tolerance and response to treatment. It is important to follow the healthcare provider’s instructions regarding dosing.

Administration

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg should be administered orally, usually in the form of tablets. It can be taken with or without food. Patients should swallow the tablets whole without chewing or crushing them.

Side Effects

Common side effects of Deroximel DR Capsule (Enteric Coated Pellets) 231 mg may include:

Flushing or redness of the skin
Gastrointestinal issues such as nausea, diarrhea, or abdominal pain
Headache

Serious side effects, although less common, may include liver enzyme elevations and severe allergic reactions.

Toxicity

Signs of toxicity may include severe gastrointestinal symptoms, liver dysfunction, or unusual bleeding or bruising. In case of suspected overdose or severe adverse effects, seek immediate medical attention.

Precautions

- Monitor liver function tests regularly, as Deroximel DR Capsule (Enteric Coated Pellets) 231 mg can cause liver enzyme elevations. - Use with caution in patients with a history of gastrointestinal disorders or those at risk for liver disease. - Patients should be advised about the potential for flushing and other common side effects.

Interaction

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg may interact with other medications that affect liver enzyme function or immune system activity. Inform your healthcare provider about all other medications and supplements you are taking to avoid potential interactions.

Disease Interaction

Patients with pre-existing liver conditions or gastrointestinal diseases should use Deroximel DR Capsule (Enteric Coated Pellets) 231 mg with caution. Regular monitoring is recommended to manage any potential complications related to these conditions.

Drug Interaction

Potential interactions may occur with drugs that affect liver metabolism or immune modulation. Consult your healthcare provider before starting any new medications or supplements while on Deroximel DR Capsule (Enteric Coated Pellets) 231 mg.

Food Interactions

There are no significant food interactions with Deroximel DR Capsule (Enteric Coated Pellets) 231 mg. However, maintaining a balanced diet can support overall health and potentially reduce gastrointestinal side effects.

Pregnancy Use

The safety of Deroximel DR Capsule (Enteric Coated Pellets) 231 mg during pregnancy has not been well-established. It should be used during pregnancy only if the benefits outweigh the risks, and under the guidance of a healthcare provider.

Lactation Use

It is unknown if Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is excreted in breast milk. Caution is advised when using this medication during lactation. Consult your healthcare provider to discuss potential risks and benefits.

Acute Overdose

In case of acute overdose, seek immediate medical attention. Symptoms may include severe gastrointestinal distress and potential liver dysfunction. Treatment focuses on supportive care and symptom management.

Contraindication

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is contraindicated in patients with known hypersensitivity to the drug or its components. It should also be used with caution in individuals with severe liver disease.

Use Direction

Follow the prescribed dosing regimen and administration instructions carefully. Regular follow-up appointments are necessary to monitor the effectiveness and safety of the treatment.

Storage Conditions

Store Deroximel DR Capsule (Enteric Coated Pellets) 231 mg at room temperature, away from moisture and heat. Keep out of reach of children and dispose of any unused medication according to local regulations.

Volume of Distribution

The volume of distribution of Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is not specifically well-defined, as it is dependent on the drug's distribution in the bloodstream and its conversion to active metabolites.

Half Life

The half-life of Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is approximately 1 to 2 hours, but the effects may last longer due to the drug's active metabolite, monomethyl fumarate.

Clearance

Deroximel DR Capsule (Enteric Coated Pellets) 231 mg is primarily cleared through renal excretion. The rate of clearance can be influenced by factors such as kidney function and concurrent medications.

See in details version Deroximel DR Capsule (Enteric Coated Pellets) 231 mg also Deroximel DR Capsule (Enteric Coated Pellets) 231 mg in bangla